Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis

Review only identified 1 RCT (n=593) which suggests tofacitinib is superior to placebo for maintenance of clinical and endoscopic remission at 52 weeks in participants with moderate‐to‐severe disease in remission. Optimal dose for maintenance therapy is unknown.


Cochrane Database of Systematic Reviews